Abstract
To provide a more definitive assessment of the efficacy and safety of tacrolimus therapy in comparison with cyclosporin, the extended follow-up of the European multicentre study is reported. Two-year Kaplan-Meier estimates indicated significant reductions in acute (tacrolimus 45.4%, cyclosporine 55.8%; P = 0.006), refractory (1.2% versus 6.4%; P = 0.003) and chronic rejection (2.0% versus 6.9%; P = 0.015) despite significantly lower steroid usage in patients receiving tacrolimus therapy. Patient and graft survival rates (80.6% versus 74.8% and 74.5% versus 70.0%, respectively) were also superior, although these failed to reach statistical significance. Safety profiles were comparable for most major categories (including renal, neurological and glucose metabolic disorders) and in certain aspects were more favourable for tacrolimus. Hypertension (28.0% versus 39.6%, P < 0.01) and cytomegalovirus infection (14.8% versus 22.3%, P < 0.01), two events with important long-term clinical consequences, were reported significantly less frequently. Hirsutism (0.0% versus 8.7%, P < 0.01) and gum hyperplasia (0.0% versus 2.3%, P < 0.05) were absent in patients receiving tacrolimus. Tacrolimus appears to provide effective and safe long-term immunosuppression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bismuth H for the European FK506 multicenter liver study group (1995) Comparison of FK 506- and cyclosporine-based immunosuppression: FK506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. Transplant Proc 27: 45 - 49
Bismuth H, Samuel D, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Groth C (1994) Focus on intractable rejection: 6-month results of the European multicentre study of FK 506 and cyclosporin A. Transplant Int 7 [Suppl 1]: S3 — S6
Christe W (1994) Neurological disorders in liver and kidney transplant recipients. Transplant Proc 26: 3175 - 3176
Devlin J, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C (1994) Renal complications and development of hypertension in the European study of FK506 and cyclosporin in primary liver transplant recipients. Transplant Int 7 [Suppl 1]: S22—S26 S 150
Ericzon B, Groth C, Bismuth H, Caine 9. R, McMaster P, Neuhaus P, Otto G, Pichlmayr R, Williams R (1994) Glu-cose metabolism in liver transplant recipients treated with FK 506 or cy- 10. closporin in the European multicentre study. Transplant Int 7 [Suppl 1]: S11 — S14
European FK506 multicentre liver study group (1994) Randomised trial 11. comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423 - 428
Frei U, Wagner K (1994) Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. Transplant Proc 26: 12. 3270 - 3271
Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, Takaya S, Ales- siani M, Demetris A, Bronster O, Martin M, Mieles L, Selby R, Reyes J, Doyle H, Stieber A, Casavilla A, Starzl T (1991) A randomized trial of primary liver transplantation under immuno- 13. suppression with FK 506 vs cyclosporine. Transplant Proc 23: 2977 - 2983
McMaster P (1994) Patient and graft survival in the European multicentre liver study — FK 506 vs cyclosporin A. Transplant Int 7 [Suppl] 11: S32 — S36
Neuhaus PJ (1994) Optimised first-line FK506-based protocol in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. Transplant Proc 26: 3264 - 3266
Neuhaus P, McMaster P, Caine R, Pichlmayr R, Otto G, Williams R, Bismuth H, Groth C (1994) Neurological complications in the European multi-centre study of FK 506 and cyclosporin in primary liver transplantation. Transplant Int 7 [Supp11]: S27 — S31
Otto G, Bleyl J, Neuhaus P, McMaster P, Caine R, Pichlmayr R, Williams R, Bismuth H, Groth C (1994) Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin I primary liver transplantation. Transplant Int 7 [Sup-pl 11: S7 — S10
Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, McMichael JP, Todo S (1995) Randomized trialomania? The multicenter liver transplant trials. Lancet 346: 1346 - 1350
The European FK506 multicentre liver study group (1994) Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK 506-based immunosuppression. Transplant Proc 26: 3260 - 3263
The U.S. multicenter FK 506 liver study group (1994) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110 - 1115
Todo S, Fung JJ, Tzakis A, Demetris AJ, Jain A, Alessiani M, Takaya S, Day R, Gordon R, Starzl TE (1991) One hun- dred ten consecutive primary ortho- topic liver transplants under FK506 in adults. Transplant Proc 23: 1397 - 1402
Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Caine R, Otto G, Williams R, Bismuth H, Groth C (1994) Optimal FK506 dosage in patients under primary immunosuppression following liver transplantation. Transplant Int 7 [Suppl 1]: S58 — S63
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Williams, R. et al. (1996). Two-year data from the European multicentre tacrolimus (FK 506) liver study. In: Mühlbacher, F., et al. Transplant International . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00818-8_36
Download citation
DOI: https://doi.org/10.1007/978-3-662-00818-8_36
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-61024-3
Online ISBN: 978-3-662-00818-8
eBook Packages: Springer Book Archive